Chemoprevention and breast cancer
Breast and ovarian cancer risks
Chemoprevention and breast cancer
Chemoprevention and ovarian cancer
Close surveillance for breast cancer
Fifteen-year
results of a randomized phase III trial of fenretinide to prevent second
breast cancer
U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T.
Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn
and G. De Palo Annals of Oncology. Volume 17, Number 7: p. 1065-1071, July,
2006.
Statins
reduce breast cancer risk: a case control study in US female veterans
R.
Kochhar, V. Khurana, H. Bejjanki, G. Caldito, C. Fort, American
Society of Clinical Oncologists. (abstract # 514), May 2005. (Annual
conference proceedings abstract)
Factor
V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast
cancer on adjuvant tamoxifen
J. E. Garber, S. Halabi, E. Kaplan, S.
Edge, L. Dressler, E. Paskett, N. Berliner, Cancer and Leukemia Group.
American Society of Clinical Oncologists. (abstract # 508), May 2005. (Annual
conference proceedings abstract)
Cardiovascular
risk associated with celecoxib in a clinical trial for colorectal adenoma
prevention
SD Solomon, McMurray JJ, Pfeffer MA, Wittes J, Fowler R,
Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention
with Celecoxib (APC) Study Investigators. New
England Journal of Medicine.
Volume 17, Number 11: p. 1071-80, March 2005.
Results
of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after
completion of 5 years' adjuvant treatment for breast cancer
Anthony
Howell, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G,
Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group. Lancet. Volume
365, Number 9453: p. 60-62, January 2005.
Breast
cancer and nonsteroidal anti-inflammatory drugs: Prospective results from
the women’s health initiative
Randall E. Harris, Rowan T. Chlebowski,
Rebecca D. Jackson, David J. Frid, Joao L. Ascenseo, Garnet Anderson, Aimee
Loar, Rebecca J. Rodabough, Emily White and Anne McTiernan. Cancer
Research.
Volume: 63, Issue 18: p. 6096-6101, September 15, 2003.
A
gonadotropin-releasing hormone agonist (Gnrha)-based chemoprevention regimen
that reduces mammographic density in Brca carriers while maintaining good
quality of life (Qol), bone density, and reproductive options
J. Weitzel,
S. Buys, M. C. Pike, A. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald,
K. R. Blazer, D. V. Spicer. American Society
of Clinical Oncologists. Volume
22: p. 94, (abstract # 374), June 2003. (Annual conference proceedings
abstract)
Effects
of Tamoxifen on benign breast disease in women at high risk for breast
cancer
Elizabeth Tan-Chiu, Jiping Wang, Joseph P. Costantino, Soonmyung
Paik, Cheryl Butch, D. Lawrence Wickerham, Bernard Fisher, Norman Wolmark. Journal
of the National Cancer Institute. Volume 95, Number 4: p. 302-307,
February 2003. (Full text)
Oral
contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation
carriers
Steven A. Narod, Marie-Pierre Dubé, Jan Klijn, Jan
Lubinski, Henry T. Lynch, Parviz Ghadirian, Diane Provencher, Ketil Heimdal,
Pal Moller, Mark Robson, Kenneth Offit, Claudine Isaacs, Barbara Weber,
Eitan Friedman, Ruth Gershoni-Baruch, Gad Rennert, Barbara Pasini, Theresa
Wagner, Mary Daly, Judy E. Garber, Susan L. Neuhausen, Peter Ainsworth,
Hakan Olsson, Gareth Evans, Michael Osborne, Fergus Couch, William D. Foulkes,
Ellen Warner, Charmaine Kim-Sing, Olufunmilayo Olopade, Nadine Tung, Howard
M. Saal, Jeffrey Weitzel, Sofia Merajver, Marion Gauthier-Villars, Helena
Jernstrom, Ping Sun, Jean-Sebastien Brunet. Journal
of the National Cancer Institute. Volume 94, Number 23: p. 1773-1779, December 2002.
Tamoxifen
and breast cancer incidence among women with inherited mutations in BRCA1
and BRCA2
Mary-Claire King, PhD; Sam Wieand, PhD; Kathryn Hale, BS;
Ming Lee, PhD; Tom Walsh, PhD; Kelly Owens, PhD; Jonathan Tait, MD, PhD;
Leslie Ford, MD; Barbara K. Dunn, MD, PhD; Joseph Costantino, DrPH; Lawrence
Wickerham, MD; Norman Wolmark, MD; Bernard Fisher, MD. Journal
of the American Medical Association. Volume 286: p. 2251-2256, November 2001.
Tamoxifen and risk of contralateral breast cancer in BRCA1 And BRCA2 mutation carriers: A case-control study Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H, Hereditary Breast Cancer Clinical Study Group. Lancet. Volume 356, Issue 9245: p. 1876-81, December 2000.
Tamoxifen
for prevention of breast cancer: Report of the National Surgical Adjuvant
Breast and Bowel Project P-1 Study
Bernard Fisher, Joseph P. Costantino,
D. Lawrence Wickerham, Carol K. Redmond, Maureen Kavanah, Walter M. Cronin,
Victor Vogel, André Robidoux, Nikolay Dimitrov, James Atkins, Mary
Daly, Samuel Wieand, Elizabeth Tan-Chiu, Leslie Ford, Norman Wolmark, and
other National Surgical Adjuvant Breast and Bowel Project Investigators.
Journal of the National Cancer Institute. Volume 90, Number 18: p. 1371-1388,
September 1998.